More than one million patients across North, South and Central America have been successfully treated with Levulan® Photodynamic Therapy, a non-invasive, topical light-based treatment for actinic keratosis, the red, scaly lesions caused by overexposure to the sun. Based on a light-sensitive, naturally occurring compound in the body and discovered by researchers at Queen’s University and Royal Military College, this treatment offers a faster, safer and more effective treatment for this precancerous skin condition. Under PARTEQ's guidance, this research breakthrough formed the basis of DUSA Pharmaceuticals Inc., and it remains the basis for DUSA today.
In 2007, PARTEQ inventors Drs. Kennedy and Pottier received the Manning Innovation Foundation’s $100,000 Principal Award, in recognition of the impact of their work. The scientific impact of their work has been equally profound, resulting in more than 1,000 academic citations in one journal alone, and stimulating studies into the potential of this light-based therapeutic approach across a vast field of applications.